Can microneedling be safely performed on a patient with psoriasis, and what are the recommended conditions and precautions?

Microneedling in Psoriasis: Safety and Recommendations

Microneedling should NOT be performed as a standard treatment procedure on active psoriatic plaques, as it represents a form of trauma that can trigger the Koebner phenomenon—the development of new psoriatic lesions at sites of skin injury.

Understanding the Koebner Phenomenon Risk

Psoriasis is highly susceptible to trauma-induced flares. The established guidelines emphasize that psoriatic lesions are "easily irritated" and can become unstable with physical manipulation 1. Any procedure causing controlled dermal wounding—which is precisely the mechanism of microneedling—poses a theoretical risk of:

• Triggering new psoriatic plaques at treatment sites
• Worsening existing lesions through inflammatory activation
• Converting stable plaque psoriasis to more unstable, eruptive forms

Current Evidence Landscape

While recent research explores microneedle technology as a drug delivery platform for anti-psoriatic medications 2, 3, 4, this is fundamentally different from cosmetic microneedling procedures. The research focuses on:

• Dissolving microneedles loaded with biologics (secukinumab) or immunomodulators 5
• Transdermal delivery systems to bypass topical penetration barriers 3
• Minimally invasive alternatives to systemic therapy 6

Critical distinction: These are investigational drug delivery devices, not cosmetic rejuvenation procedures. None of the established psoriasis guidelines 1, 7, 8, 9, 10 mention microneedling as an accepted treatment modality.

When Microneedling Might Be Considered (With Extreme Caution)

If microneedling is being contemplated in a psoriasis patient, the following conditions must be met:

Absolute Requirements:

• Disease must be in complete remission with no active plaques for at least 6 months
• No history of Koebner phenomenon in the patient
• Treatment area must be completely clear of any psoriatic involvement
• Patient must understand the risk of triggering new lesions

Relative Contraindications:

• Unstable psoriasis of any type (guttate, pustular, erythrodermic) 1
• Recent flares or disease activity within 6 months
• Patients on systemic immunosuppression (methotrexate, cyclosporine, biologics) where wound healing may be compromised 7, 10
• Areas with previous psoriatic involvement, even if currently clear

Clinical Decision Algorithm

Step 1: Assess current disease activity

• Active plaques anywhere on body → Do not proceed
• Complete remission >6 months → Proceed to Step 2

Step 2: Evaluate Koebner history

• Any history of trauma-induced lesions → Do not proceed
• No Koebner history documented → Proceed to Step 3

Step 3: Examine treatment area specifically

• Any scale, erythema, or plaque → Do not proceed
• Completely normal skin → Proceed to Step 4

Step 4: Review current medications

• On biologics, methotrexate, cyclosporine → Defer procedure or consult dermatology
• On topicals only or no treatment → May proceed with informed consent

Step 5: Obtain explicit informed consent

• Document discussion of Koebner risk
• Establish monitoring plan for new lesions
• Ensure patient will report any changes immediately

Monitoring After Procedure (If Performed)

• Week 1-2: Daily self-examination for new papules or plaques
• Week 3-4: Weekly examination
• Months 2-3: Monthly follow-up
• Immediate dermatology referral if any new lesions develop

Common Pitfalls to Avoid

1. Assuming "mild" psoriasis is safe: Even limited disease can demonstrate Koebner phenomenon
2. Treating "clear" areas without full body examination: Psoriasis elsewhere indicates active disease state
3. Proceeding during medication transitions: Disease stability is uncertain during treatment changes
4. Ignoring patient history of trauma-induced flares: This is the most predictive factor

The Bottom Line

The safest recommendation is to avoid microneedling in any patient with a psoriasis diagnosis, regardless of current disease activity. The risk-benefit ratio does not favor cosmetic procedures that deliberately traumatize skin in a condition defined by pathologic response to injury. If the patient insists on proceeding despite counseling, ensure complete disease remission, document extensively, and maintain close surveillance for Koebner phenomenon development.

The emerging research on microneedle drug delivery systems 2, 5 represents a distinct therapeutic approach under investigation, not a justification for cosmetic microneedling procedures in psoriasis patients.